Precigen (PGEN) Competitors $1.39 +0.02 (+1.46%) Closing price 04:00 PM EasternExtended Trading$1.38 0.00 (-0.36%) As of 05:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PGEN vs. BEAM, GLPG, CNTA, AGIO, KNSA, ANIP, APGE, JANX, KYMR, and ARWRShould you be buying Precigen stock or one of its competitors? The main competitors of Precigen include Beam Therapeutics (BEAM), Galapagos (GLPG), Centessa Pharmaceuticals (CNTA), Agios Pharmaceuticals (AGIO), Kiniksa Pharmaceuticals (KNSA), ANI Pharmaceuticals (ANIP), Apogee Therapeutics (APGE), Janux Therapeutics (JANX), Kymera Therapeutics (KYMR), and Arrowhead Pharmaceuticals (ARWR). These companies are all part of the "pharmaceutical products" industry. Precigen vs. Beam Therapeutics Galapagos Centessa Pharmaceuticals Agios Pharmaceuticals Kiniksa Pharmaceuticals ANI Pharmaceuticals Apogee Therapeutics Janux Therapeutics Kymera Therapeutics Arrowhead Pharmaceuticals Beam Therapeutics (NASDAQ:BEAM) and Precigen (NASDAQ:PGEN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, community ranking, analyst recommendations, institutional ownership and media sentiment. Does the media prefer BEAM or PGEN? In the previous week, Beam Therapeutics had 8 more articles in the media than Precigen. MarketBeat recorded 9 mentions for Beam Therapeutics and 1 mentions for Precigen. Precigen's average media sentiment score of 0.94 beat Beam Therapeutics' score of 0.41 indicating that Precigen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Precigen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher earnings and valuation, BEAM or PGEN? Precigen has lower revenue, but higher earnings than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBeam Therapeutics$63.52M26.66-$132.53M-$4.58-3.71Precigen$3.93M104.51-$95.90M-$0.48-2.91 Does the MarketBeat Community prefer BEAM or PGEN? Precigen received 371 more outperform votes than Beam Therapeutics when rated by MarketBeat users. Likewise, 67.44% of users gave Precigen an outperform vote while only 58.93% of users gave Beam Therapeutics an outperform vote. CompanyUnderperformOutperformBeam TherapeuticsOutperform Votes6658.93% Underperform Votes4641.07% PrecigenOutperform Votes43767.44% Underperform Votes21132.56% Do institutionals and insiders believe in BEAM or PGEN? 99.7% of Beam Therapeutics shares are held by institutional investors. Comparatively, 33.5% of Precigen shares are held by institutional investors. 4.2% of Beam Therapeutics shares are held by company insiders. Comparatively, 44.9% of Precigen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is BEAM or PGEN more profitable? Beam Therapeutics has a net margin of -41.07% compared to Precigen's net margin of -3,521.68%. Beam Therapeutics' return on equity of -16.22% beat Precigen's return on equity.Company Net Margins Return on Equity Return on Assets Beam Therapeutics-41.07% -16.22% -10.94% Precigen -3,521.68%-123.06%-87.33% Which has more risk & volatility, BEAM or PGEN? Beam Therapeutics has a beta of 2.02, meaning that its stock price is 102% more volatile than the S&P 500. Comparatively, Precigen has a beta of 1.7, meaning that its stock price is 70% more volatile than the S&P 500. Do analysts recommend BEAM or PGEN? Beam Therapeutics currently has a consensus price target of $49.45, suggesting a potential upside of 191.42%. Precigen has a consensus price target of $7.00, suggesting a potential upside of 401.79%. Given Precigen's higher possible upside, analysts plainly believe Precigen is more favorable than Beam Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Beam Therapeutics 0 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 3.00Precigen 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryBeam Therapeutics and Precigen tied by winning 9 of the 18 factors compared between the two stocks. Remove Ads Get Precigen News Delivered to You Automatically Sign up to receive the latest news and ratings for PGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PGEN vs. The Competition Export to ExcelMetricPrecigenPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$410.19M$6.48B$5.29B$7.37BDividend YieldN/A3.24%5.11%4.31%P/E Ratio-2.546.8321.7017.78Price / Sales104.51228.36378.1494.74Price / CashN/A65.6738.1534.64Price / Book2.915.876.423.98Net Income-$95.90M$142.26M$3.20B$247.33M7 Day Performance8.98%7.58%4.73%4.31%1 Month Performance-21.63%-14.16%-9.88%-7.80%1 Year Performance6.49%-9.81%10.77%1.40% Precigen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PGENPrecigen3.4851 of 5 stars$1.39+1.5%$7.00+403.6%+0.7%$408.72M$3.93M-2.53190BEAMBeam Therapeutics2.9564 of 5 stars$15.26-0.1%$49.45+224.1%-35.3%$1.52B$63.52M-8.67510Short Interest ↑High Trading VolumeGLPGGalapagos0.6548 of 5 stars$23.08-2.8%$25.33+9.8%-16.9%$1.52B$275.65M0.001,123Upcoming EarningsHigh Trading VolumeCNTACentessa Pharmaceuticals2.9154 of 5 stars$11.31-3.2%$27.71+145.2%+7.3%$1.51B$6.85M-7.39200Gap DownHigh Trading VolumeAGIOAgios Pharmaceuticals3.8667 of 5 stars$25.91+0.6%$56.57+118.3%-5.8%$1.48B$36.50M2.29390Analyst RevisionKNSAKiniksa Pharmaceuticals2.4342 of 5 stars$20.26-0.5%$37.17+83.4%+17.6%$1.47B$423.24M-144.71220Upcoming EarningsAnalyst ForecastInsider TradeNews CoverageANIPANI Pharmaceuticals3.4906 of 5 stars$66.98-0.8%$79.75+19.1%+5.6%$1.46B$614.38M-121.79600Analyst UpgradeNews CoverageAPGEApogee Therapeutics2.0729 of 5 stars$32.21-0.4%$92.17+186.2%-36.8%$1.45BN/A-13.3191JANXJanux Therapeutics2.6913 of 5 stars$24.45-5.1%$92.44+278.1%-43.2%$1.45B$10.59M-20.9030Positive NewsKYMRKymera Therapeutics1.4123 of 5 stars$21.95-0.6%$56.36+156.8%-26.3%$1.43B$47.07M-9.38170Positive NewsGap UpARWRArrowhead Pharmaceuticals3.4179 of 5 stars$10.20-4.5%$41.44+306.5%-52.0%$1.40B$2.50M-1.97400News Coverage Remove Ads Related Companies and Tools Related Companies BEAM Competitors GLPG Competitors CNTA Competitors AGIO Competitors KNSA Competitors ANIP Competitors APGE Competitors JANX Competitors KYMR Competitors ARWR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PGEN) was last updated on 4/17/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Precigen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Precigen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
